Literature DB >> 29942487

Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4.

Suaka Kagbo-Kue1, Taiwo Ajose1, Nicolas Bakinde1.   

Abstract

Entities:  

Year:  2018        PMID: 29942487      PMCID: PMC5963149          DOI: 10.1186/s13578-018-0234-2

Source DB:  PubMed          Journal:  Cell Biosci        ISSN: 2045-3701            Impact factor:   7.133


× No keyword cloud information.
Dear Editor, It was interesting to read the article Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4 published by Ying et al. Several studies have explored the mechanism of Aspirin in preventing colorectal cancer (CRC) and also that of metastases in CRC [1-4] but this study was noteworthy in that it explored the mechanism of Aspirin in preventing liver metastases in CRC. According to the National Cancer Institute, CRC is the second leading cause of cancer deaths in the United States [5]. The liver is the most common site of metastases in CRC and significantly affects survival [6, 7]. Aspirin is chemopreventive in different types of cancers especially CRC [1]. Tumorigenesis and CRC metastasis are hypothesized to occur by different mechanisms involving cancer stems cells (CSC), the overexpression of cyclooxygenase-2 (COX-2) and epidermal growth factor (EGFR), and other downstream effects in the early phases of CRC [2-4]; Aspirin is postulated to play its role by modifying these epigenetic events, especially among patients with mutated-PIK3CA [4]. Aspirin taken chronically at doses ranging from 75 to 200 mg is associated with reduced mortality and increased survival [3, 4]. The results reported by the authors demonstrate that lipopolysaccharide (LPS) induced the metastasis and epithelial-mesenchymal transition (EMT) phenotype of colon cancer cells via a toll-like receptor 4 (TLR4) dependent manner. TLR4 thus mediates the biologic function of LPS. Previous research has also indicated that LPS could activate the nuclear factor kappa B (NFkB) signal transduction which also plays a role in the EMT process [8]. LPS thus potentiated the metastatic potential of colon cancer cells in the cell lines in this study (C26 and HCT116). Treatment with Aspirin decreased TLR4 expression by decreasing LPS-induced EMT which further leads to downregulation of NFkB [7]. In agreement with the findings from the study, Aspirin might act as an inhibitor in the LPS-induced metastasis of colon cancer and TLR4 could be used as a prognostic marker and a potential therapeutic target [7]. Another class of drugs to consider is Statins. Statins have also been shown to inhibit LPS-induced EMT via the downregulation of TLR4 and NFkB in human biliary epithelial cells, and could be an additional agent for reducing the metastatic potential of colon cancer cells [9]. Based on this study, Aspirin is an inexpensive drug that could potentially reduce the mortality of CRC. Further studies are needed to explore the application to independent cohorts of patients, to validate that the potential benefits outweigh the possible risks, and to determine the role of other inexpensive drugs such as Statins, so as to increase survival in CRC.
  8 in total

1.  Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer.

Authors:  Hefei Wang; Bing Liu; Jing Wang; Jinglin Li; Ying Gong; Sisi Li; Chunli Wang; Bai Cui; Xiaoyuan Xue; Mengying Yang; Wenjun Fan; Zhijie Kang; Muhammad Kamran; Jie Xu; Pengfei Tian; Yuanyuan Luo; Zhijie Hou; Lin Dong; Yanling Ren; Man Li; Qingping Wen; Wei Cheng; Lingzhi Xu; Ling Wang; Quentin Liu
Journal:  Cell Physiol Biochem       Date:  2017-11-27

Review 2.  Aspirin, cyclooxygenase inhibition and colorectal cancer.

Authors:  Carlos Sostres; Carla Jerusalen Gargallo; Angel Lanas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

3.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

4.  Statin pretreatment inhibits the lipopolysaccharide-induced epithelial-mesenchymal transition via the downregulation of toll-like receptor 4 and nuclear factor-κB in human biliary epithelial cells.

Authors:  Yangmi Kim; Eun Jeoung Lee; Hee Kyung Jang; Chan Hyung Kim; Dae-Ghon Kim; Joung-Ho Han; Seon Mee Park
Journal:  J Gastroenterol Hepatol       Date:  2016-06       Impact factor: 4.029

Review 5.  New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia.

Authors:  Luigia Di Francesco; Luilli Antonio López Contreras; Angela Sacco; Paola Patrignani
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  Colorectal cancer: Metastases to a single organ.

Authors:  Sina Vatandoust; Timothy J Price; Christos S Karapetis
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

7.  Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B Pathway.

Authors:  Mingyang Han; Yucheng Song; Xuedong Zhang
Journal:  Pharmacogn Mag       Date:  2016-05-11       Impact factor: 1.085

8.  Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4.

Authors:  Jun Ying; Hai-Yang Zhou; Peng Liu; Qing You; Fei Kuang; Yi-Nan Shen; Zhi-Qian Hu
Journal:  Cell Biosci       Date:  2018-01-04       Impact factor: 7.133

  8 in total
  3 in total

Review 1.  Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.

Authors:  Altaf Mohammed; Nagendra Sastry Yarla; Venkateshwar Madka; Chinthalapally V Rao
Journal:  Int J Mol Sci       Date:  2018-08-08       Impact factor: 5.923

2.  Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation.

Authors:  Jinbo Fu; Yiming Xu; Yushan Yang; Yun Liu; Lulu Ma; Yiyao Zhang
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

3.  Identification of Target Genes Related to Sulfasalazine in Triple-Negative Breast Cancer Through Network Pharmacology.

Authors:  Haochen Yu; Ke Hu; Tao Zhang; Haoyu Ren
Journal:  Med Sci Monit       Date:  2020-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.